SKIN Stock Beauty Health Company (The) (SKIN, $1.5) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 9, 2024

GET DAILY SIGNALS

Get AI intraday signals

SKIN - Beauty Health Company (The)

MACD signal

View

Odds of UP Trend

Price: $1.5

Daily change: $0 (0%)

Daily volume: 802.7K

Industry: Household/Personal Care

SKIN in upward trend: price rose above 50-day moving average on December 17, 2024

SKIN moved above its 50-day moving average on December 17, 2024 date and that indicates a change from a downward trend to an upward trend. In of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 06, 2024. You may want to consider a long position or call options on SKIN as a result. In of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SKIN just turned positive on December 09, 2024. Looking at past instances where SKIN's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SKIN advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 121 cases where SKIN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for SKIN crossed bearishly below the 50-day moving average on November 25, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKIN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SKIN broke above its upper Bollinger Band on December 17, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SKIN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.905) is normal, around the industry mean (16.934). P/E Ratio (53.476) is within average values for comparable stocks, (201.433). Projected Growth (PEG Ratio) (0.858) is also within normal values, averaging (3.832). Dividend Yield (0.000) settles around the average of (0.107) among similar stocks. P/S Ratio (1.418) is also within normal values, averaging (113.563).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKIN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.